Diana T. Perkinson, M.D.
OMEROSAbout Diana T. Perkinson, M.D.
Independent director at Omeros since 2023 (age 71). Dual board-certified nephrologist and internist; currently a physician at MD² International (concierge medicine) since 2009. Education: M.D. University of Alabama; B.S. Birmingham-Southern College; nephrology fellowship at University of Washington. Prior roles include clinical assistant professor (UW) and medical director, transplantation at Swedish Hospital; former USAF major and dialysis unit director at Wilford Hall Medical Center .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| University of Washington (Division of Nephrology) | Clinical Assistant Professor | 1987–2009 | Academic oversight and training in nephrology |
| Swedish Hospital | Medical Director, Transplantation | 1996–2007 | Oversight of transplant-related care and programs |
| Minor & James Medical (Seattle) | Nephrology & Internal Medicine Physician | 1987–2009 | Clinical practice in nephrology and internal medicine |
| United States Air Force (Wilford Hall Medical Center) | Major; Director, Dialysis Unit | 1984–1987 | Led dialysis operations at a major military medical center |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| MD² International LLC | Physician | 2009–present | Concierge medicine network |
Board Governance
| Committee | Role | Since | Chair? |
|---|---|---|---|
| Nominating & Governance | Member | April 2024 | No (chair is Thomas J. Cable) |
| Scientific | Member | May 2023 | No (chair is Thomas F. Bumol, Ph.D.) |
- Independence: Board determined Dr. Perkinson meets Nasdaq and SEC independence standards .
- Attendance: Board met 5 times in 2024; other than Dr. Shah, all directors attended ≥75% of board and applicable committee meetings (Dr. Perkinson met the ≥75% threshold) .
- Lead Independent Director: Thomas J. Cable; responsibilities include chairing executive sessions and coordinating independent directors .
- Board diversity: The board identifies Dr. Perkinson as female and an underrepresented minority .
Fixed Compensation
Omeros non-employee director policy (cash):
- Annual Board retainer: $50,000; Committee member fees: Audit $10,000, Compensation $7,500, Nominating & Governance $5,000, Scientific $5,000; Chairs: Audit $20,000, Compensation $15,000, Nominating & Governance $10,000, Scientific $10,000; Lead Independent Director retainer: $25,000 .
2024 actual compensation (cash):
| Year | Fees Earned or Paid in Cash ($) |
|---|---|
| 2024 | $58,750 |
Performance Compensation
Omeros non-employee director policy (equity):
- Initial grant: stock options for 30,000 shares upon appointment, vesting in equal annual installments over 3 years.
- Annual grant: stock options for 15,000 shares each annual meeting, vesting in full the day prior to the next annual meeting; exercise price equals the closing price on grant date .
Her equity awards and holdings:
| Item | Detail |
|---|---|
| Options held (Dec 31, 2024) | 45,000 options outstanding |
| Director 2024 option grant (FY) | Option award grant-date fair value: $49,073 |
Form 4 transactions (director equity awards):
| Transaction Date | Filing Date | Type | Securities Transacted | Exercise Price | Security | Post-Transaction Ownership |
|---|---|---|---|---|---|---|
| 2024-06-06 | 2024-06-07 | Award (Option) | 15,000 | $3.91 | Stock Option (Right to Buy) | 15,000 |
| 2025-06-27 | 2025-07-01 | Award (Option) | 15,000 | $3.20 | Stock Option (Right to Buy) | 15,000 |
- Performance metrics: Director equity compensation is time-based; no revenue/EBITDA/TSR performance conditions disclosed for directors .
Other Directorships & Interlocks
- No other public company directorships disclosed in the proxy biography for Dr. Perkinson .
Expertise & Qualifications
- Clinical expertise in nephrology and internal medicine; transplant program leadership .
- Academic experience and military medical leadership .
- Diversity adds perspective per board’s diversity policy .
Equity Ownership
Beneficial ownership (as of May 23, 2025):
| Item | Amount | % of Class |
|---|---|---|
| Exercisable Stock Options (within 60 days) | 35,000 | — |
| Total Beneficially Owned (incl. exercisable options) | 35,000 | <1% |
Policies affecting alignment:
- Hedging prohibited; directors cannot engage in short sales or derivative hedges on Omeros stock .
- Pledging restricted; requires preclearance and board/audit committee approval .
Governance Assessment
-
Committee service and independence: Dr. Perkinson serves on two independent committees (Nominating & Governance; Scientific), supporting board oversight of governance and R&D risk; formally determined independent by the board .
-
Attendance: Met ≥75% attendance threshold in 2024, supporting engagement and effectiveness .
-
Compensation mix: Balanced cash ($58,750) and time-based option awards ($49,073) in 2024; equity vests time-based, aligning with long-term shareholder value without short-term metric gaming .
-
Ownership/insider activity: Beneficial ownership via options; recent Form 4s reflect standard annual director option awards; no pledging/hedging permitted under policy, reducing alignment risks .
-
Related parties: No related-party transactions disclosed involving Dr. Perkinson; Omeros requires audit committee pre-approval for any such transactions and evaluates independence impacts .
-
Broader governance signals: 2024 say-on-pay support declined to 69%, with board engagement and subsequent clarification of bonus caps (150% of target) indicating responsiveness; while executive pay-focused, it reflects governance attentiveness that supports investor confidence .
-
RED FLAGS: None disclosed specific to Dr. Perkinson (no attendance shortfall, no related-party transactions, no hedging/pledging). Broader cautionary note: annual meeting attendance by only two of eight directors in 2024 (names not disclosed), but no indication Dr. Perkinson was absent .